Compare Ascendis Pharma A/S (ASND) vs Canadian Natural Resources Ltd. (CNQ) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Canadian Natural Resources Ltd. — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Canadian Natural Resources Ltd. trades at $42.5 (market cap $86.83B). The key difference: Canadian Natural Resources Ltd. is far larger — about 4.9× Ascendis Pharma A/S's market cap, and Canadian Natural Resources Ltd. pays a 4.21% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | CNQ | |
|---|---|---|
Market Cap | $17.74B | $86.83B |
Sector | Health | Energy |
52-Week High | $277.18 | $50.55 |
52-Week Low | $163.32 | $29.31 |
Enterprise Value | $18.11B | $98.06B |
Dividend Yield | — | 4.21% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
CNQ trades at $41.81, down 0.17% on the day, with a bullish technical signal and strong fundamentals. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $0.85 exceeding the $0.74 estimate. Valuation metrics appear attractive with a P/E of 11.8 and EV/EBITDA of 6.54, while profitability remains high with a net income margin of 24.5% and ROE of 25.81%.
The outlook is positive given consistent earnings outperformance, a 75% analyst buy rating, and strong free cash flow supporting shareholder returns. Key risks include oil price volatility and rising debt levels, but the company's operational stability and dividend yield near 4% provide a cushion for investors seeking energy exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Canadian Natural Resources Ltd.
Canadian Natural Resources is one of the largest oil and natural gas producers in western Canada, supplemented by operations in the North Sea and Offshore Africa. The company's portfolio includes light and medium oil, heavy oil, bitumen, synthetic oil, natural gas liquids, and natural gas. Production averaged 1.16 million barrels of oil equivalent per day in 2020, and the company estimates that it holds over 11.5 billion boe of proven and probable crude oil and natural gas reserves.
Read more on CNQ →
